Non-alcoholic fatty liver disease (NAFLD) is becoming the most common liver disease worldwide, and its burden is expected to increase due to the growing epidemic of obesity and diabetes. The key challenge among NAFLD patients is to identify those with advanced fibrosis (F3F4), who are at high risk of developing complications and will benefit from specialized management and treatment with new pharmacotherapies when they are approved. Liver biopsy appears unrealistic and unsuitable in practice, given the large number of high-risk patients and its well-known limitations. Non-invasive sequential algorithms using fibrosis-4 index as first-line test, followed by vibration-controlled transient elastography or patented blood test, are the best strategy for case finding of high-risk subjects. In fact, they are now recommended by several international guidelines, and should be used and disseminated to increase awareness among physicians beyond liver clinics where most NAFLD patients are seen.
Citations
Citations to this article as recorded by
Integration of PNPLA3 and TM6SF2 genotypes provides incremental improvement in advanced fibrosis prediction among MASLD patients with type 2 diabetes mellitus Dong Yun Kim, Hyun-Soo Zhang, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Hyun Woong Lee, Heon Yung Gee, Jung Il Lee, Jun Yong Park JHEP Reports.2026; 8(2): 101713. CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis Zobair M. Younossi, Shira Zelber-Sagi, Jeffrey V. Lazarus, Vincent Wai-Sun Wong, Yusuf Yilmaz, Ajay Duseja, Yuichiro Eguchi, Laurent Castera, Mário Guimarães Pessoa, Claudia Pinto Oliveira, Mohamed El-Kassas, Emmanuel Tsochatzis, Jian-Gao Fan, C. Wendy Sp Gastroenterology.2025; 169(5): 1017. CrossRef
Comparative evaluation of FIB-3 and FIB-4 indices for liver fibrosis screening in workplace-based health checkups Kota Fukai, Shoko Nakazawa, Kosuke Sakai, Yuko Furuya, Yuya Watanabe, Toru Honda, Takeshi Hayashi, Toru Nakagawa, Masaaki Korenaga, Masayuki Tatemichi Journal of Occupational Health.2025;[Epub] CrossRef
Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway Jianping Zhu, Yuzhen Chen, Yidi Han, Ji Li, Fahrul Nurkolis PLOS One.2025; 20(9): e0331303. CrossRef
Sugar Rationing in the First 1000 Days After Conception and Long-term Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Major Adverse Liver Outcomes: A Natural Experiment Study Jiazhen Zheng, Zhen Zhou, Jinghan Huang, Qiang Tu, Haisheng Wu, Quan Yang, Qi Qi, Wenbo Huang, Junchun Shen, Xianbo Wu, Chuang Yang, Daniel J. Cuthbertson Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu Journal of Gastroenterology and Hepatology.2024; 39(1): 193. CrossRef
Liver Biopsy Handling of Metabolic-Associated Fatty Liver Disease (MAFLD): the Children’s Hospital of Eastern Ontario grossing protocol Consolato M. Sergi, Mohit Kehar, Carolina Jimenez-Rivera Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef
Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease Samar A. Zailaie, Basmah B. Khoja, Jumana J. Siddiqui, Mohammad H. Mawardi, Emily Heaphy, Amjad Aljagthmi, Consolato M. Sergi Non-Coding RNA.2024; 10(1): 10. CrossRef
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, Soroor Owrangi, Nagashree Gundu-Rao, Romona Satchi, James M. Paik Clinical Gastroenterology and Hepatology.2024; 22(10): 1999. CrossRef
Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(Suppl): S147. CrossRef
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how? Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease Ji-Won Park, Ki Tae Suk Clinical and Molecular Hepatology.2023; 29(2): 408. CrossRef
Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis Thierry Poynard, Olivier Deckmyn, Valentina Peta, Valérie Paradis, Jean‐Francois Gautier, Angélique Brzustowski, Pierre Bedossa, Laurent Castera, Stanislas Pol, Dominique Valla Alimentary Pharmacology & Therapeutics.2023; 58(9): 888. CrossRef
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia Thierry Poynard, Olivier Deckmyn, Valentina Peta, Mehdi Sakka, Pascal Lebray, Joseph Moussalli, Raluca Pais, Chantal Housset, Vlad Ratziu, Eric Pasmant, Dominique Thabut Hepatology Communications.2023;[Epub] CrossRef
MASLD and aspartame: are new studies in the horizon? Consolato M. Sergi Frontiers in Medicine.2023;[Epub] CrossRef
First
Prev
